BRPI0519661A2 - uso de agonistas de ppar para o tratamento da falÊncia cardÍaca congestiva - Google Patents

uso de agonistas de ppar para o tratamento da falÊncia cardÍaca congestiva

Info

Publication number
BRPI0519661A2
BRPI0519661A2 BRPI0519661-2A BRPI0519661A BRPI0519661A2 BR PI0519661 A2 BRPI0519661 A2 BR PI0519661A2 BR PI0519661 A BRPI0519661 A BR PI0519661A BR PI0519661 A2 BRPI0519661 A2 BR PI0519661A2
Authority
BR
Brazil
Prior art keywords
heart failure
congestive heart
ppar agonists
treat congestive
treat
Prior art date
Application number
BRPI0519661-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Wolfgang Linz
Stefan Schaefer
Eugen Falk
Hans-Ludwig Schaefer
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of BRPI0519661A2 publication Critical patent/BRPI0519661A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BRPI0519661-2A 2004-12-17 2005-12-06 uso de agonistas de ppar para o tratamento da falÊncia cardÍaca congestiva BRPI0519661A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04029946A EP1671633A1 (en) 2004-12-17 2004-12-17 Use of PPAR agonists for the treatment of congestive heart failure
PCT/EP2005/013046 WO2006063715A1 (en) 2004-12-17 2005-12-06 Use of ppar agonists for the treatment of congestive heart failure

Publications (1)

Publication Number Publication Date
BRPI0519661A2 true BRPI0519661A2 (pt) 2009-03-03

Family

ID=34927823

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519661-2A BRPI0519661A2 (pt) 2004-12-17 2005-12-06 uso de agonistas de ppar para o tratamento da falÊncia cardÍaca congestiva

Country Status (16)

Country Link
US (1) US7601863B2 (cg-RX-API-DMAC7.html)
EP (2) EP1671633A1 (cg-RX-API-DMAC7.html)
JP (1) JP2008524129A (cg-RX-API-DMAC7.html)
KR (1) KR20070086332A (cg-RX-API-DMAC7.html)
CN (1) CN101072557A (cg-RX-API-DMAC7.html)
AR (1) AR051723A1 (cg-RX-API-DMAC7.html)
AT (1) ATE498400T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005315920A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0519661A2 (cg-RX-API-DMAC7.html)
CA (1) CA2590391A1 (cg-RX-API-DMAC7.html)
DE (1) DE602005026443D1 (cg-RX-API-DMAC7.html)
IL (1) IL183810A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007006678A (cg-RX-API-DMAC7.html)
MY (1) MY141010A (cg-RX-API-DMAC7.html)
TW (1) TW200635584A (cg-RX-API-DMAC7.html)
WO (1) WO2006063715A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399777B2 (en) 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
JP7017563B2 (ja) 2016-10-05 2022-02-08 ミトブリッジ，インコーポレーテッド Ｐｐａｒアゴニスト化合物の結晶性および塩形態

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20010795A2 (en) * 1999-04-28 2003-02-28 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
WO2003020269A1 (de) * 2001-08-31 2003-03-13 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, verfahren zu ihrer herstellung und ihre verwendung als ppar-aktivatoren
WO2004082621A2 (en) * 2003-03-15 2004-09-30 Bethesda Pharmaceuticals, Inc. Novel ppar agonists, pharmaceutical compositions and uses thereof
US6989462B2 (en) * 2003-03-25 2006-01-24 Sanofi-Aventis Deutschland Gmbh Synthesis of 2-chloromethyl-6-methylbenzoic ester
US6987118B2 (en) * 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators

Also Published As

Publication number Publication date
TW200635584A (en) 2006-10-16
ATE498400T1 (de) 2011-03-15
MX2007006678A (es) 2007-08-14
EP1671633A1 (en) 2006-06-21
US7601863B2 (en) 2009-10-13
CA2590391A1 (en) 2006-06-22
IL183810A0 (en) 2007-10-31
AU2005315920A1 (en) 2006-06-22
KR20070086332A (ko) 2007-08-27
AR051723A1 (es) 2007-01-31
DE602005026443D1 (de) 2011-03-31
JP2008524129A (ja) 2008-07-10
WO2006063715A1 (en) 2006-06-22
EP1827425A1 (en) 2007-09-05
EP1827425B1 (en) 2011-02-16
CN101072557A (zh) 2007-11-14
US20080039512A1 (en) 2008-02-14
MY141010A (en) 2010-02-25

Similar Documents

Publication Publication Date Title
EA200802213A1 (ru) Способы лечения заболеваний крови
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
UA85559C2 (en) Aminobenzophenone compounds
GEP20084499B (en) USE OF INTERFERON-ß FOR TREATMENT OF RENAL FAILURE
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
HRP20090281T1 (hr) 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti
DK1532269T3 (da) 1L1RL-1 som markør for kardiovaskulær sygdom
NO20075068L (no) Lipocalinprotein
EA200300829A1 (ru) Производные 1-арил- или 1-алкилсульфонилбензазола в качестве лигандов 5-гидрокситриптамина-6
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
NO20070247L (no) Amino-5,5-difenylimidazolonderivater for inhibisjon av beta-sekretase
NO20074824L (no) Forlengelse av tid til sykdomsprogresjon eller overlevelse hos kreftpasienter
DE602004022982D1 (de) Verwendung von treprostinil zur verbesserung der nierenfunktion
MY145340A (en) Milnacipran for the long-term treatment of fibromyalgia syndrome
EA200301142A1 (ru) Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
NO20055649L (no) Substituert dihydrokinazolin med antiviale egenskaper
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
HRP20090498T1 (hr) Kombinacija r,r-glikopirolata, roliprama i budesonida za liječenje upalnih oboljenja
BRPI0416268A (pt) composições de delta-9-thc e métodos para o tratamento de sintomas associados à esclerose múltipla
DK1423384T3 (da) Pyridinderivater som Raf kinaseinhibitorer
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
EA200701845A1 (ru) Рофлумиласт для лечения сахарного диабета

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2203 DE 26/03/2013.